Literature DB >> 15801933

Reproducibility of forearm vasodilator response to intra-arterial infusion of calcitonin gene-related peptide assessed by venous occlusion plethysmography.

Floris H M Vanmolkot1, Jan N J M de Hoon.   

Abstract

AIMS: To assess the reproducibility of the forearm blood flow (FBF) response to intra-arterial infusion of calcitonin-gene related peptide (CGRP), measured by venous occlusion plethysmography. In addition, to compare different ways of expressing the FBF response and perform sample size calculations.
METHODS: On two separate visits, CGRP (10 ng min(-1) dl(-1) forearm) was infused for 45 min into the brachial artery of six healthy subjects. Reproducibility was assessed by calculating mean difference, repeatability coefficient, within-subject coefficient of variation (WCV) and intraclass correlation coefficient.
RESULTS: CGRP increased FBF from 2.8 +/- 0.4 and 3.2 +/- 0.7 (at baseline) to 15.4 +/- 1.4 and 15.2 +/- 1.5 ml min(-1) dl(-1) forearm (at 45 min) on visits 1 and 2, respectively (P < 0.0001 for both visits). Mean difference in FBF at 45 min between both visits was 0.3 ml min(-1) dl(-1) forearm (repeatability coefficient: 4.1 ml min(-1) dl(-1) forearm). This FBF response appeared to be more reproducible when expressed as absolute FBF in the infused arm (WCV 11%) compared with absolute FBF-ratio between both arms (WCV 37%), percentage change from baseline in FBF in the infused arm (WCV 29%) and percentage change from baseline in FBF-ratio (WCV 40%). When expressed as absolute FBF, a sample size of five (95% confidence interval: 2-12) subjects gives 90% power at a type I error probability of 0.05 to detect a 25% shift in FBF response.
CONCLUSIONS: Intra-arterial infusion of CGRP results in a forearm vasodilator response which is reproducible between days. This response is most reproducible when expressed as absolute FBF. The presented methodology provides a suitable pharmacodynamic model to assess the in vivo activity of CGRP-receptor antagonists in a small number of subjects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15801933      PMCID: PMC1884797          DOI: 10.1111/j.1365-2125.2005.02333.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  39 in total

Review 1.  Venous occlusion plethysmography in cardiovascular research: methodology and clinical applications.

Authors:  I B Wilkinson; D J Webb
Journal:  Br J Clin Pharmacol       Date:  2001-12       Impact factor: 4.335

2.  Power and sample size calculations. A review and computer program.

Authors:  W D Dupont; W D Plummer
Journal:  Control Clin Trials       Date:  1990-04

3.  Variability and reproducibility of arterial and venous circulation parameters in the forearm and calf measured at one-week intervals.

Authors:  H U Altenkirch; G Koch; H E Koralewski
Journal:  Vasa       Date:  1990       Impact factor: 1.961

Review 4.  Development of CGRP antagonists for the treatment of migraine.

Authors:  H Doods
Journal:  Curr Opin Investig Drugs       Date:  2001-09

5.  Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks.

Authors:  P Sarchielli; A Alberti; M Codini; A Floridi; V Gallai
Journal:  Cephalalgia       Date:  2000-12       Impact factor: 6.292

6.  Pharmacokinetics and pharmacodynamic effects of ABT-627, an oral ETA selective endothelin antagonist, in humans.

Authors:  M C Verhaar; A Y Grahn; A W Van Weerdt; M L Honing; P J Morrison; Y P Yang; R J Padley; T J Rabelink
Journal:  Br J Clin Pharmacol       Date:  2000-06       Impact factor: 4.335

7.  Systemic ETA receptor antagonism with BQ-123 blocks ET-1 induced forearm vasoconstriction and decreases peripheral vascular resistance in healthy men.

Authors:  J C Spratt; J Goddard; N Patel; F E Strachan; A J Rankin; D J Webb
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

Review 8.  Migraine and beyond: cardiovascular therapeutic potential for CGRP modulators.

Authors:  S A Doggrell
Journal:  Expert Opin Investig Drugs       Date:  2001-06       Impact factor: 6.206

Review 9.  Calcitonin gene-related peptide (CGRP) and the pathophysiology of headache: therapeutic implications.

Authors:  L Edvinsson
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

10.  Repeatability of local forearm vasoconstriction to endothelin-1 measured by venous occlusion plethysmography.

Authors:  Fiona E Strachan; David E Newby; David G Sciberras; Jacqueline B McCrea; Michael R Goldberg; David J Webb
Journal:  Br J Clin Pharmacol       Date:  2002-10       Impact factor: 4.335

View more
  4 in total

Review 1.  Development of anti-migraine therapeutics using the capsaicin-induced dermal blood flow model.

Authors:  Linde Buntinx; Steve Vermeersch; Jan de Hoon
Journal:  Br J Clin Pharmacol       Date:  2015-10-06       Impact factor: 4.335

2.  Reproducibility of the capsaicin-induced dermal blood flow response as assessed by laser Doppler perfusion imaging.

Authors:  B J Van der Schueren; J N de Hoon; F H Vanmolkot; A Van Hecken; M Depre; S A Kane; I De Lepeleire; S R Sinclair
Journal:  Br J Clin Pharmacol       Date:  2007-06-19       Impact factor: 4.335

3.  Endothelial function in migraine: a cross-sectional study.

Authors:  Floris H Vanmolkot; Jan N de Hoon
Journal:  BMC Neurol       Date:  2010-12-01       Impact factor: 2.474

4.  First-in-human development of a pharmacodynamic biomarker for PAC1 receptor antagonists using intradermal injections of maxadilan.

Authors:  Heleen Marynissen; Linde Buntinx; Dorien Bamps; Marleen Depre; Els Ampe; Anne Van Hecken; Kristin Gabriel; Steve Sands; Gabriel Vargas; Jan de Hoon
Journal:  Clin Transl Sci       Date:  2022-05-27       Impact factor: 4.438

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.